Current best evidence on prescribed drugs

Pills
Drugdocs Logo

Current best evidence on prescribed drugs

Pills
HomeDrugsNewsAboutContact

DRUG ▾

ABCDEFGHIJKLMNOPQRSTUVWXYZ

DRUG

CLASS

News

Tildrakizumab-asmn

(Ilumya®)

Tildrakizumab-asmn

Drug updated on 3/28/2024

Dosage FormInjectable (subcutaneous; 100 mg/mL)
Drug ClassInterleukin-23 antagonists
Ongoing and
Completed Studies		ClinicalTrials.gov

Indication

  • Indicated for the treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy.

Summary
This AI-generated content is provided without warranty and may be inaccurate or outdated; it should be used only as a research starting point, with no liability accepted for reliance on it. Learn more.

  • Tildrakizumab-asmn (Ilumya) is indicated for the treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy.
  • A total of 15 systematic reviews and meta-analyses were reviewed to gather information about this drug's safety and effectiveness.
  • In terms of efficacy, Ilumya showed significant improvement in clinical outcomes such as Psoriasis Area and Severity Index scores and American College of Rheumatology 20 response rates when used to treat moderate-to-severe plaque psoriasis and Psoriatic Arthritis.
  • Compared to other drugs like ixekizumab, risankizumab, brodalumab which target IL-17, IL-12/23, Ilumya's efficacy was slightly lower but it improved nail psoriasis outcomes significantly - an important consideration for those with psoriatic arthritis.
  • The most commonly reported adverse events across treatments included nasopharyngitis, upper respiratory tract infections, injection site reactions headache,and diarrhea; however tildrakizmub had no significant difference in serious adverse events compared to placebo suggesting a favorable safety profile relative its efficacy.
  • Among all IL-23 inhibitors including Tildrakizmub (Ilumiya), Risankuzimba was highlighted having the most favourable benefit-risk profile in long term use cases according to these documents.
  • Subgroup analyses suggested that a dose of 200 mg might offer better efficacy in patients weighing over 90 kg indicating that dosage considerations based on patient characteristics could be crucial while prescribing this medication.
  • While some agents like ixekinzmub secukinzmub have high probabilities achieving desired outcome more research needed biological-naïve participants baseline disease severity subgroups further understand comparative safety efficiency among different patient subgroups.

Product Monograph / Prescribing Information

Document TitleYearSource
Ilumya (tildrakizumab-asmn) Prescribing Information2020Sun Pharmaceuticals

Systematic Reviews / Meta-Analyses

Document TitleYearSource
Efficacy and safety of nail psoriasis targeted therapies: a systematic review.2023American Journal of Clinical Dermatology
Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis. 2023Cochrane Database of Systematic Reviews
Efficacy and safety of IL-23 inhibitors in the treatment of psoriatic arthritis: a meta-analysis based on randomized controlled trials. 2023Immunologic research
Adverse Effects of Anti-Interleukin-23 Agents Employed in Patients with Psoriasis: A Systematic Review. 2022Dermatology
Comparative efficacy and safety of biologics in moderate to severe plaque psoriasis: a multiple-treatments meta-analysis.2021Journal of the German Society of Dermatology
Comparative efficacy and relative ranking of biologics and oral therapies for moderate-to-severe plaque psoriasis: a network meta-analysis. 2021Dermatology and Therapy
Comparative safety and benefit-risk profile of biologics and oral treatment for moderate-to-severe plaque psoriasis: a network meta-analysis of clinical trial data.2021Journal of the American Academy of Dermatology
Therapeutic update of biologics and small molecules for scalp psoriasis: a systematic review. 2021Dermatologic Therapy
A systematic review with network meta-analysis of the available biologic therapies for psoriatic disease domains. 2021Frontiers in Medicine
Clinical review report: tildrakizumab (Ilumya). 2021CADTH
A systematic literature review and bucher indirect comparison: tildrakizumab versus guselkumab.2020Journal of Health Economics and Outcomes Research
Systematic review on rapidity of onset of action for interleukin-17 and interleukin-23 inhibitors for psoriasis.2020Journal of the European Academy of Dermatology and Venereology
Comparative efficacy and safety of biologics in moderate to severe plaque psoriasis: a multiple‐treatments meta‐analysis.2020Journal of the German Society of Dermatology
Systemic pharmacological treatments for chronic plaque psoriasis: a network meta‐analysis.2020Cochrane Database of Systematic Reviews
Tildrakizumab: An Evidence-Based Review of Its Use in the Treatment of Moderate-to-Severe Chronic Plaque Psoriasis. 2020Therapeutics and Clinical Risk Management
Tildrakizumab for treating moderate to severe plaque psoriasis.2019NICE
Short-term efficacy and safety of IL-17, IL-12/23, and IL-23 inhibitors brodalumab, secukinumab, ixekizumab, ustekinumab, guselkumab, tildrakizumab, and risankizumab for the treatment of moderate to severe plaque psoriasis: A systematic review and network meta-analysis of randomized controlled trials.2019Journal of Immunology Research
Targeted immunomodulators for the treatment of moderate-to-severe plaque psoriasis: effectiveness and value. 2019ICER
A systematic review and meta-analysis of the efficacy and safety of the interleukin (IL)-12/23 and IL-17 inhibitors ustekinumab, secukinumab, ixekizumab, brodalumab, guselkumab and tildrakizumab for the treatment of moderate to severe plaque psoriasis.2018The Journal of Dermatological Treatment
Public assessment report: Ilumetri.2018EMA

Clinical Practice Guidelines

Document TitleYearSource
EuroGuiDerm guideline on the systemic treatment of psoriasis vulgaris - part 1: treatment and monitoring recommendations. 2020Journal of the European Academy of Dermatology and Venerology
Guideline Number: CG053, Ver. 2 Ilumya (tildrakizumab-asmn). 2020Ctfassets.net
Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics. 2019Journal of the American Academy of Dermatology